Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 20/20 | 0.71 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.70 |
| ▸ | FAP | Q12884 | 2/20 | 0.68 |
| ▸ | POU2F2 | P09086 | 1/20 | 0.68 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.68 |
| ▸ | POU2F1 | P14859 | 1/20 | 0.68 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.68 |
| ▸ | HRH2 | P25021 | 1/20 | 0.68 |
| ▸ | MC4R | P32245 | 1/20 | 0.68 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.68 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.68 |
| ▸ | GHSR | Q92847 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3974586 | 1.00 | DPP4 (0.71) | DPP4CHRM1FAPPOU2F2ADORA3 | |
| SCHEMBL3971944 | 0.91 | DPP4 (0.70) | DPP4CHRM1FAPPOU2F2ADORA3 | |
| SCHEMBL3971947 | 0.91 | DPP4 (0.70) | DPP4CHRM1FAPPOU2F2ADORA3 | |
| SCHEMBL3968046 | 0.90 | DPP4 (0.70) | DPP4CHRM1FAPPOU2F2ADORA3 | |
| SCHEMBL3968050 | 0.90 | DPP4 (0.70) | DPP4CHRM1FAPPOU2F2ADORA3 | |
| SCHEMBL3972486 | 0.88 | DPP4 (0.74) | DPP4CHRM1 | |
| SCHEMBL3972484 | 0.88 | DPP4 (0.74) | DPP4CHRM1 | |
| SCHEMBL3974730 | 0.87 | DPP4 (0.71) | DPP4CHRM1FAPPOU2F2ADORA3 | |
| SCHEMBL3974725 | 0.87 | DPP4 (0.71) | DPP4CHRM1FAPPOU2F2ADORA3 | |
| SCHEMBL637226 | 0.86 | DPP4 (0.72) | DPP4CHRM1FAPPOU2F2ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8697868-B2 | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-04-15 | — | — | US | disclosed |
| US-20090137801-A1 | 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-05-28 | — | — | US | disclosed |
| US-7501426-B2 | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137801-A1 | 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | DPP8, DPP4, DPP7 | DPP4 2/4885CHRM1 1139/4885FAP 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.